• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles invests in Swiss biotech Kareus

Quintiles invests in Swiss biotech Kareus

June 14, 2011
CenterWatch Staff

In further evidence of a shift toward more fundamental risk-sharing in drug development between biopharmaceutical companies and CROs, Quintiles is making a significant investment in Swiss biotech Kareus Therapeutics as part of a broad strategic alliance to move two of Kareus’ pre-clinical programs through clinical trials, according to PharmaTimes.

Quintiles will make an undisclosed investment in Kareus, a privately owned biotechnology company focused on developing novel therapeutics to address high unmet medical need in areas such as central nervous system disorders, metabolic diseases and cardiovascular conditions.


The investment will be split between an equity stake and access to clinical services on a shared-risk basis. In June 2010, Quintiles said it would invest up to $2 million in Australia’s Prana Biotechnology to help support a planned phase II study with PBT2, a compound for Alzheimer’s disease.


Kareus plans to file an investigational new drug (IND) application in the U.S. for KU-046, a “first-in-class” new chemical entity discovered in-house for the treatment of Alzheimer’s disease. 

Kareus also has identified a lead series of molecules that demonstrate potent, long-lasting insulin sensitization with a broad therapeutic window for the treatment of Type-2 diabetes, the company said. It will select a clinical candidate from this lead series for development later this year. 

Quintiles will conduct phase I proof-of-relevance trials for both KU-046 and the selected diabetes candidate.

The deal “is an example of how leading biotechnology companies are building partnerships that extend beyond the traditional licensing model to manage risk, increase productivity and increase value to stakeholders,” said Tom Perkins, Quintiles’ senior vice president of corporate development.

Perkins said in leveraging Quintiles’ suite of drug development services, Kareus will be able to use the company’s new phase I research unit in Hyderabad, India.

“With Quintiles as our partner, Kareus is now ideally placed to accelerate the development of our novel drug pipeline and advance the first product candidates generated by our innovative discovery platform into clinical studies,” said Patrick Doyle, head of corporate and business development at Kareus.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing